Works matching IS 21534888 AND DT 2018 AND VI 9 AND IP 4
Results: 28
Venclexta Approved in Combination for Older Adults with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 34
- Publication type:
- Article
Adcetris First FDA-Approved Drug for CD30-Expressing Peripheral T-Cell Lymphomas.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 34
- Publication type:
- Article
FDA Approves Expanded Use of HPV Vaccine Gardasil 9.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 34
- Publication type:
- Article
Truxima First Biosimilar to Rituxan FDA-Approved for Non-Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 34
- Publication type:
- Article
Xospata First Therapy Approved for Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 34
- Publication type:
- Article
PACIFIC: Practice-Changing Study in Stage III Unresectable Non-Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 33
- By:
- Publication type:
- Article
Brigatinib, New ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 32
- By:
- Publication type:
- Article
Atezolizumab plus Chemotherapy New First-Line Regimen for Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 31
- By:
- Publication type:
- Article
Vitrakvi Second Drug Approved Based on a Genetic Biomarker, Not a Tumor Type.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 30
- Publication type:
- Article
Paradigm Shift: Radiation a New Standard in Prostate Cancer with Low Metastatic Burden.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 30
- By:
- Publication type:
- Article
Daurismo New Treatment Approved for Older Adults with Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 29
- Publication type:
- Article
Udenyca, Second Biosimilar to Neulasta, FDA-Approved to Reduce Risk for Infection in Patients with Nonmyeloid Malignancies.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 29
- Publication type:
- Article
Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 28
- By:
- Publication type:
- Article
Lorbrena New Treatment Approved for Patients with Metastatic NSCLC and ALK Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 27
- Publication type:
- Article
Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 27
- Publication type:
- Article
Libtayo First Immunotherapy Approved for Advanced Cutaneous Squamous-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 25
- Publication type:
- Article
Vizimpro a New First-Line Targeted Therapy for Metastatic NSCLC with EGFR Mutations.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 24
- Publication type:
- Article
Lumoxiti a New Treatment Approved for Patients with Hairy-Cell Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 20
- Publication type:
- Article
Do No Financial Harm: How to Improve Cost Transparency in Cancer Care.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 19
- By:
- Publication type:
- Article
Addressing Financial Toxicity Through Systematic Change.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 18
- By:
- Publication type:
- Article
Practice-Changing Results: Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 16
- By:
- Publication type:
- Article
Alpelisib First Drug to Improve Outcomes in Advanced Breast Cancer with PIK3CA Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 15
- By:
- Publication type:
- Article
Poteligeo Approved for 2 Rare Types of Non-Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 14
- Publication type:
- Article
Entrectinib Effective and Safe in NTRK Fusion-Positive Solid Tumors.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 14
- By:
- Publication type:
- Article
CAR T-Cell Therapy: Can We Afford the Cure?
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 1
- Publication type:
- Article
First-Line Olaparib a New Standard in Women with Newly Diagnosed, BRCA-Positive Advanced Ovarian Cancer?
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 1
- By:
- Publication type:
- Article
Avelumab plus Axitinib a New Standard in Advanced Renal-Cell Carcinoma?
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 1
- By:
- Publication type:
- Article
Targeted Therapy Has Significant Activity as Second-Line Treatment of Cholangiocarcinoma with FGFR Mutations.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 4, p. 1
- By:
- Publication type:
- Article